| AKT1 |
AKT serine/threonine kinase 1 |
- Activation of BAD and translocation to mitochondria
- PIP3 activates AKT signaling
- PIP3 activates AKT signaling
- Downregulation of ERBB2:ERBB3 signaling
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- mTOR signalling
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the nucleus
- Negative regulation of the PI3K/AKT network
- eNOS activation
- AKT-mediated inactivation of FOXO1A
- Integrin signaling
- Deactivation of the beta-catenin transactivating complex
- CD28 dependent PI3K/Akt signaling
- CTLA4 inhibitory signaling
- G beta:gamma signalling through PI3Kgamma
- Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
- KSRP (KHSRP) binds and destabilizes mRNA
- VEGFR2 mediated vascular permeability
- TP53 Regulates Metabolic Genes
- Constitutive Signaling by AKT1 E17K in Cancer
- Interleukin-4 and Interleukin-13 signaling
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- RAB GEFs exchange GTP for GDP on RABs
- RUNX2 regulates genes involved in cell migration
- Regulation of PTEN stability and activity
- Extra-nuclear estrogen signaling
- Negative regulation of NOTCH4 signaling
- Regulation of localization of FOXO transcription factors
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- ATP
- Arsenic trioxide
- Genistein
- Inositol 1,3,4,5-Tetrakisphosphate
- Resveratrol
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
|
- PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
|
| ASL |
argininosuccinate lyase |
|
- L-Arginine
- Argininosuccinate
- 2-(N-Morpholino)-Ethanesulfonic Acid
|
- Argininosuccinic aciduria (ARGINSA); Argininosuccinate lyase deficiency
|
| BLVRB |
biliverdin reductase B |
|
- Riboflavin
- NADH
- Biliverdine IX Alpha
- Riboflavin Monophosphate
- 2'-Monophosphoadenosine 5'-Diphosphoribose
- 7,8-dimethylalloxazine
- Mesobiliverdin Iv Alpha
|
|
| CPSF1 |
cleavage and polyadenylation specific factor 1 |
- Transport of Mature mRNA Derived from an Intronless Transcript
- tRNA processing in the nucleus
- mRNA Splicing - Major Pathway
- mRNA 3'-end processing
- RNA Polymerase II Transcription Termination
- Processing of Intronless Pre-mRNAs
|
|
|
| CREB3 |
cAMP responsive element binding protein 3 |
- CREB3 factors activate genes
- CREB3 factors activate genes
|
|
|
| KASH5 |
KASH domain containing 5 |
|
|
|
| LMNA |
lamin A/C |
- XBP1(S) activates chaperone genes
- Signaling by BRAF and RAF fusions
|
|
- Restrictive dermopathy
- Emery-Dreifuss muscular dystrophy
- Dilated cardiomyopathy (DCM)
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
- Mandibuloacral dysplasia
- Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
- Limb-girdle muscular dystrophy (LGMD)
- Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
- Hutchinson-Gilford progeria syndrome
|
| NOS1 |
nitric oxide synthase 1 |
- ROS and RNS production in phagocytes
- Nitric oxide stimulates guanylate cyclase
- Ion homeostasis
|
- L-Citrulline
- L-N(Omega)-Nitroarginine-2,4-L-Diaminobutyric Amide
- Formic Acid
- 3-Bromo-7-Nitroindazole
- N-{(4s)-4-Amino-5-[(2-Aminoethyl)Amino]Pentyl}-N'-Nitroguanidine
- N-(3-(Aminomethyl)Benzyl)Acetamidine
- L-N(Omega)-Nitroarginine-(4r)-Amino-L-Proline Amide
- N-Isopropyl-N'-Hydroxyguanidine
- N-Omega-Propyl-L-Arginine
- N-Butyl-N'-Hydroxyguanidine
- S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
- N-Omega-Hydroxy-L-Arginine
- Flavin adenine dinucleotide
- Riboflavin Monophosphate
- N-(4-(2-((3-Chlorophenylmethyl)Amino)Ethyl)Phenyl)-2-Thiophecarboxamidine
- 2'-Monophosphoadenosine 5'-Diphosphoribose
- S-Ethyl-N-Phenyl-Isothiourea
- N5-(1-Imino-3-Butenyl)-L-Ornithine
- 5-N-Allyl-Arginine
- Nitroarginine
- NXN-188
- N-{(3S,4S)-4-[(6-AMINO-4-METHYLPYRIDIN-2-YL)METHYL]PYRROLIDIN-3-YL}-N'-(4-CHLOROBENZYL)ETHANE-1,2-DIAMINE
- N-{(3R,4S)-4-[(6-amino-4-methylpyridin-2-yl)methyl]pyrrolidin-3-yl}-N'-(3-chlorobenzyl)ethane-1,2-diamine
- Methylene blue
|
|
| PDGFB |
platelet derived growth factor subunit B |
- Platelet degranulation
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- Non-integrin membrane-ECM interactions
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
- Malignant pleural mesothelioma
- Glioma
|
| POR |
cytochrome p450 oxidoreductase |
- Cytochrome P450 - arranged by substrate type
|
- Flavin adenine dinucleotide
- Riboflavin Monophosphate
- 2'-Monophosphoadenosine 5'-Diphosphoribose
|
- 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
- Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
| POT1 |
protection of telomeres 1 |
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Cleavage of the damaged purine
- Meiotic synapsis
- Packaging Of Telomere Ends
- Telomere Extension By Telomerase
- DNA Damage/Telomere Stress Induced Senescence
|
|
|
| SNF8 |
SNF8 subunit of ESCRT-II |
- Endosomal Sorting Complex Required For Transport (ESCRT)
- HCMV Late Events
|
|
|
| TERF1 |
telomeric repeat binding factor 1 |
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Cleavage of the damaged purine
- Meiotic synapsis
- Packaging Of Telomere Ends
- Telomere Extension By Telomerase
- DNA Damage/Telomere Stress Induced Senescence
|
|
|
| TEX33 |
testis expressed 33 |
|
|
|
| TUT1 |
terminal uridylyl transferase 1, U6 snRNA-specific |
|
|
|
| ZNF132 |
zinc finger protein 132 |
|
|
|